HomeCompareKGTFF vs JNJ

KGTFF vs JNJ: Dividend Comparison 2026

KGTFF yields 10.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KGTFF wins by $436203.77M in total portfolio value
10 years
KGTFF
KGTFF
● Live price
10.00%
Share price
$1.10
Annual div
$0.11
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436203.80M
Annual income
$427,982,070,990.02
Full KGTFF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KGTFF vs JNJ

📍 KGTFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKGTFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KGTFF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KGTFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KGTFF
Annual income on $10K today (after 15% tax)
$850.00/yr
After 10yr DRIP, annual income (after tax)
$363,784,760,341.52/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KGTFF beats the other by $363,784,756,355.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KGTFF + JNJ for your $10,000?

KGTFF: 50%JNJ: 50%
100% JNJ50/50100% KGTFF
Portfolio after 10yr
$218101.92M
Annual income
$213,991,037,839.71/yr
Blended yield
98.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KGTFF
No analyst data
Altman Z
0.4
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KGTFF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKGTFFJNJ
Forward yield10.00%2.13%
Annual dividend / share$0.11$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$436203.80M$30.3K
Annual income after 10y$427,982,070,990.02$4,689.40
Total dividends collected$435647.34M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KGTFF vs JNJ ($10,000, DRIP)

YearKGTFF PortfolioKGTFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,700$2,000.00$10,592$272.30+$2.1KKGTFF
2$18,337$4,747.66$11,289$357.73+$7.0KKGTFF
3$32,433$12,812.76$12,123$472.89+$20.3KKGTFF
4$77,063$42,359.97$13,141$629.86+$63.9KKGTFF
5$270,590$188,131.85$14,408$846.81+$256.2KKGTFF
6$1,524,261$1,234,730.29$16,021$1,151.60+$1.51MKGTFF
7$14,631,657$13,000,698.03$18,122$1,588.22+$14.61MKGTFF
8$248,919,512$233,263,638.51$20,930$2,228.20+$248.90MKGTFF
9$7,683,863,097$7,417,519,219.51$24,792$3,191.91+$7683.84MKGTFF
10$436,203,804,504$427,982,070,990.02$30,274$4,689.40+$436203.77MKGTFF

KGTFF vs JNJ: Complete Analysis 2026

KGTFFStock

Krung Thai Bank Public Company Limited provides various commercial banking products and services. The company operates through three segments: Retail Banking, Wholesale Banking, and Treasury and Investment. It provides various retail banking products and services, including current, savings, and fixed deposit accounts; time and foreign currency deposits; personal and housing loans; debit, travel, cash and top up, and credit cards; investment services; travel, motor, and home asset insurance products; money transfer, payment and top up, foreign exchange, and overseas education services; and e-banking services. The company also offers SME loans for small and medium businesses; and international business loans. In addition, it provides corporate banking products and services comprising cash management services, such as collection, liquidity management, and transfer and payment services; fixed deposit and current accounts; foreign currency and term deposits; cards; Fx, interest rate, equity, commodity, and credit derivatives; financial advisory services related to merger and acquisition transactions; financial advisory, underwriting, and selling agent services for products offered through the equity capital markets; project finance advisory and feasibility study services, as well as e-banking services; and investment solutions, such as government and corporate bonds, structured notes, and investment units. The company provides its services through a network of branches in Thailand and various centers internationally. Krung Thai Bank Public Company Limited was founded in 1966 and is headquartered in Bangkok, Thailand.

Full KGTFF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KGTFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KGTFF vs SCHDKGTFF vs JEPIKGTFF vs OKGTFF vs KOKGTFF vs MAINKGTFF vs ABBVKGTFF vs MRKKGTFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.